ASND · Ascendis Pharma A/S
$250.25
-2.74 (-1.08%)
At close · Aug 26
Market Cap
$16.59B
Shares
65.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$250.25
Open$252.84
Day$249.16–252.84
52W close$189.74–277.18
Avg vol 30d504K
Short int3.7M · 5.6% float · 6.3d
Short vol56%
Last earningsAug 13, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
−2%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
69%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+5%
trailing
YTD return
+17%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $254 › 200d $230 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +82 funds added
Insider flow
Accumulating
Net +$681.9K over 90 days · 0% sells
Short interest
Rising
5.62% of float · ▲ +8.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
309 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
69%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $254 › 200d $230 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +82 funds added
Insider flow
Accumulating
Net +$681.9K over 90 days · 0% sells
Short interest
Rising
5.62% of float · ▲ +8.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
309 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $190
Now $250 · 69%
Range high $277
vs 200-day avg +9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASND
this stock
Ascendis Pharma A/S
|
$16.59B | +17.4% | — | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASND | -3.6% | -0.7% | +5.4% | +2.6% | +17.4% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -3.2% | -5.7% | -7.0% | +0.1% | +5.0% |
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
279 filings
276 filers
Visit website
Investor relations